Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model.

Tominaga, Naoto;Robert, Annie;Izuhara, Yuko;Ohtomo, Shuichi;Miyata, Toshio;et.al.
(2009) Nephrology — Vol. 14, n° 6, p. 581-587 (2009)

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 219.88 KB
Request a copy

Details

Authors
  • Tominaga, Naoto
    Author
  • Robert, AnnieUCLouvain
    Author
  • Izuhara, Yuko
    Author
  • Ohtomo, Shuichi
    Author
  • Van Ypersele de Strihou, CharlesUCLouvain
    Author
  • Miyata, Toshio
    Author
Show more
Abstract
Angiotensin II type 1 receptor blockers (ARB) retard the progression of hypertensive diabetic kidney disease. Clinical evidence suggests that the dose of ARB required to correct hypertension is suboptimal for renoprotection evaluated by proteinuria. No systematic, prospective study has yet evaluated separately the effect of increasing doses of ARB on blood pressure and proteinuria.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Tominaga, N., Robert, A., Izuhara, Y., Ohtomo, S., Dan, T., Chihara, K., Kurokawa, K., Van Ypersele de Strihou, C., & Miyata, T. (2009). Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model. Nephrology, 14(6), 581-587. https://doi.org/10.1111/j.1440-1797.2009.01143.x (Original work published 2009)